All In Biotech

Drug Trial Radar · NCT00864071

A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Fasting Conditions

A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study Of Griseofulvin 125 mg/5 mL Suspension Versus Grifulvin V® 125 mg/5 mL Suspension In Normal, Healthy, Non-Smoking Male And Female Subjects

Last checked: Nov 19, 2026Latest source record: Aug 16, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Nov 2005

Primary completion

Nov 2005

Study completion Nov 2005

Sponsor

Lead sponsor
Actavis Inc.Industry
Sponsor type
Industry
First posted
Mar 18, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To compare the rate and extent of absorption of griseofulvin from a test formulation of Griseofulvin 125 mg/5 mL Suspension versus the reference Grifulvin V® 125 mg/5 mL Suspension under fasting conditions.

Conditions

  • Healthy

Interventions

  • Griseofulvin 125 mg/5 mL Suspension, single doseDrug

    A: Experimental Subjects received Alpharma formulated products under fasting conditions

  • Grifulvin V® 125 mg/5 mL Suspension, single doseDrug

    B: Active comparator Subjects received Ortho Neutrogena formulated products under fasting conditions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate and Extend of AbsorptionTime frame: 120 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Biovail Contract Research (A Division of Biovail Corporation)

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.